Osteo Arthritis Knee Clinical Trial
Official title:
Self Cranial Electrical Stimulation for Pain in Older Adults With Knee Osteoarthritis (Self CES for Knee Pain)
Verified date | October 2020 |
Source | The University of Texas Health Science Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the feasibility, safety, and preliminary efficacy of a two-week self Cranial Electrical Stimulation(CES) on pain in older adults with knee osteoarthritis(OA)
Status | Completed |
Enrollment | 30 |
Est. completion date | November 21, 2019 |
Est. primary completion date | November 21, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 85 Years |
Eligibility | Inclusion Criteria: - have self-reported unilateral or bilateral knee OA pain, according to American College of Rheumatology criteria - have had knee OA pain in the past 3 months with an average of at least 30 on a 100 Numeric Rating Scale (NRS) for pain - can speak and read English - have a device with internet access that can be used for secure video conferencing for real- time remote supervision - have no plan to change medication regimens for pain throughout the trial - are able to travel to the coordinating center - are willing and able to provide written informed consent prior to enrollment Exclusion Criteria: - history of brain surgery, brain tumor, seizure,stroke, or intracranial metal implantation - serious medical illness, such as uncontrolled hypertension (i.e., systolic blood pressure/ diastolic blood pressure = 150/95 mm Hg)heart failure, or history of acute myocardial infarction - alcohol/substance abuse - cognitive impairment - pregnancy or lactation - hospitalization within the preceding year for psychiatric illness |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Pain as Assessed by a Numeric Rating Scale (NRS) for Pain | The NRS total score ranges from 0 (no pain) to 100 (most intense pain imaginable). | week 2 | |
Primary | Clinical Pain as Assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | The WOMAC ranges from 0 to 96, with higher scores indicating worse osteoarthritis (OA) pain-related symptoms | week 2 | |
Secondary | Experimental Pain Sensitivity as Measured Using a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Threshold (HPTH) | In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH), heat pain tolerance (HPTO), pressure pain threshold (PPT), and Conditioned Pain Modulation (CPM).
To assess HPTH, heat stimuli were delivered to the participant's knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when the sensation ''first becomes painful" to assess the heat pain threshold (HPTH). |
week 2 | |
Secondary | Experimental Pain Sensitivity as Measured Using a Multimodal Quantitative Sensory Testing (QST) Battery - Heat Pain Tolerance (HPTO) | In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH), heat pain tolerance (HPTO), pressure pain threshold (PPT), and Conditioned Pain Modulation (CPM).
To assess HPTO, heat stimuli were delivered to the participant's knee using a computer-controlled TSAII NeuroSensory Analyzer. From a baseline of 32 degrees Celsius, the temperature increased by 0.5 degrees Celsius per second until the participants responded by pressing a button to stop heat stimuli. Participants were instructed to press the button when they ''no longer feel able to tolerate the pain" to assess their heat pain tolerance (HPTO). |
week 2 | |
Secondary | Experimental Pain Sensitivity as Measured Using a Multimodal Quantitative Sensory Testing (QST) Battery - Pressure Pain Threshold (PPT) | In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH), heat pain tolerance (HPTO), pressure pain threshold (PPT), and Conditioned Pain Modulation (CPM).
To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm^2) per second to the participant's knee. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful" to assess pressure pain threshold (PPT). |
week 2 | |
Secondary | Experimental Pain Sensitivity as Measured Using a Multimodal Quantitative Sensory Testing (QST) Battery - Conditioned Pain Modulation (CPM) | In order to measure experimental pain sensitivity, a multimodal Quantitative Sensory Testing (QST) battery will be completed: heat pain threshold (HPTH), heat pain tolerance (HPTO), pressure pain threshold (PPT), and Conditioned Pain Modulation (CPM).
CPM was assessed as the change in PPT on the trapezius immediately after the immersion of the contralateral hand up to the wrist in a cold-water bath (Neslab, Portsmouth, NH) at 12 degrees C for one minute. [To assess PPT, a handheld digital pressure algometer (Wagner, Greenwich, CT) was applied at a constant rate of 0.3 kilograms force per centimeter squared (kgf/cm^2) per second to the participant's trapezius. Participants were asked to notify the experimenter when the pressure sensation ''first becomes painful" to assess pressure pain threshold (PPT).] |
week 2 | |
Secondary | Psychosocial Symptoms as Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) - Anxiety Short Form | The 7-item PROMIS Anxiety Short Form assesses the pure domain of anxiety in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety. | week 2 | |
Secondary | Psychosocial Symptoms as Measured by PROMIS - Depression Short Form | The 8-item PROMIS Depression Short Form assesses the pure domain of depression in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression. | week 2 | |
Secondary | Psychosocial Symptoms as Measured by PROMIS - Sleep Disturbance Short Form | The 8-item PROMIS Sleep Disturbance Short Form assesses the pure domain of sleep disturbance in individuals age 18 and older, and each item on the measure is rated on a 5-point scale (1=never; 2=rarely;3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance. | week 2 | |
Secondary | Psychosocial Symptoms as Measured by the Pain Catastrophizing Scale (PCS) | The Pain Catastrophizing Scale (PCS) consists of 13 items assessing three components of catastrophizing: rumination, magnification, and helplessness. It is measured using the 0 (not at all) to 4 (all the time) scale. Total score ranges from 0 to 52, with higher scores indicating greater pain catastrophizing. | week 2 | |
Secondary | Number of Participants With a Significant Change in Pain-related Cortical Response on Average as Assessed by a Continuous Wave, Multichannel Functional Near-infrared Spectroscopy (fNIRS) Imaging System | Pain-related cortical response will be measured using a continuous-wave, multichannel fNIRS imaging system (LIGHTNIRS, Shimadzu, Kyoto, Japan) with three semiconductor lasers at 780, 805, and 830 nm. Optical recordings will be collected during thermal pain stimulation. | baseline, week 2 | |
Secondary | Participant Satisfaction With Treatment Using the Client Satisfaction Questionnaire (CSQ-8) | The CSQ-8 comprises eight items that are summed to yield an overall score of 8-32, with higher scores indicating greater satisfaction. | week 2 | |
Secondary | Feasibility as Measured by the Number of Participants That Completed the Full CES Protocol | week 2 | ||
Secondary | Feasibility as Indicated by Participant's Cranial Electrical Stimulation (CES) Experience | CES experience will be measured on a 10-item scale, with each item rated 0-10 and 0 being strongly disagree and 10 being strongly agree. Total score ranges from 0 to 100, with higher scores indicating a better CES experience.
Question 1. It was easy to prepare the device and accessories Question 2. The device was unnecessarily complex Question 3. The device was easy to use Question 4. I felt the video conferences with a technical person were helpful Question 5. I would imagine that most people would learn to use this device quickly Question 6. The device was cumbersome to use Question 7. I felt confident using the device Question 8. I needed to learn a lot of things before I could get going with this device Question 9. The effectiveness of the treatment increased over the course of treatment Question 10. I felt that transcranial electrical stimulation treatment benefited me |
week 2 | |
Secondary | Tolerability as Indicated by Number of Participants With Possible Side Effects of Treatment | Measurement of presence and severity of possible side effects of treatment on a 0 (not at all) to 10 (highest degree) scale.If any side effects are reported, the degree of relatedness to the intervention will be assessed on a 5-point scale. | week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04040985 -
Legion Primary Safety and Efficacy
|
N/A | |
Active, not recruiting |
NCT04525950 -
Robotized Navigation Compared to Conventional Technique in Total Knee Replacement
|
N/A | |
Recruiting |
NCT04320914 -
High Intensity Laser Therapy (Classes IV) and Ibuprofen Gel Phonophoresis for Treating Knee Osteoarthritis
|
N/A | |
Completed |
NCT03886142 -
Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis
|
N/A | |
Terminated |
NCT04072055 -
MOTO Post-marketing Surveillance Study
|
||
Not yet recruiting |
NCT06385275 -
The Role of Vitamin K on Knee Osteoarthritis Outcomes
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05290818 -
Total Versus Robotic Assisted Unicompartmental Knee Replacement
|
N/A | |
Withdrawn |
NCT03271229 -
Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee
|
Phase 2 | |
Recruiting |
NCT05505552 -
Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:
|
N/A | |
Recruiting |
NCT05992038 -
Use of a Putty as Gap Filler in Open-wedge Osteotomy
|
N/A | |
Recruiting |
NCT06066684 -
Pain Phenotyping in Knee OA: a Pilot Trial
|
||
Completed |
NCT03847324 -
Physiotherapy and Therapeutic Education on Patients With Pain Catastrophism Scheduled for a Total Knee Arthroplasty
|
N/A | |
Recruiting |
NCT05126485 -
Biofeedback Retention in Individuals With AKA
|
Early Phase 1 | |
Completed |
NCT04956393 -
The SOAR (Stop OsteoARthritis) Program Proof-of-Concept Study
|
N/A | |
Recruiting |
NCT04541342 -
Arthroscopic Evaluation of Cartilage Regeneration After Opening-wedge High Tibial Osteotomy
|
N/A | |
Completed |
NCT04391842 -
Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis
|
Phase 1 | |
Completed |
NCT03680807 -
Power Production in Older Adults With Knee Osteoarthritis
|
||
Completed |
NCT03783455 -
Effectiveness of Five Intraarticular Strategies on Knee Osteoarthritis
|
N/A | |
Not yet recruiting |
NCT06264362 -
Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia
|
N/A | |
Completed |
NCT05089253 -
Effect of Physical Therapy Modalities in Osteoarthritis
|
N/A |